Literature DB >> 25966226

Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer.

B L Xing1, T Li2, Z H Tang2, L Jiao2, S M Ge2, X Qiang2, J OuYang2.   

Abstract

DNA methylation plays an important role in carcinogenesis and cancer development. In this study, we examined gene methylation in epithelial ovarian cancer (EOC) using cationic conjugated polymer (CCP)-based fluorescence resonance energy transfer (FRET) to evaluate the application of cumulative methylation alternations of genes associated with cancer antigen 125 for early cancer diagnosis. The methylation status of 3 genes (Ras association domain family 1 isoform A, RASSF1A; opioid-binding protein/cell adhesion molecule, OPCML; homeobox A9, HOXA9) were examined and compared in 35 EOC samples and 11 normal ovarian tissue samples using CCP-based FRET. Gene methylation levels were clustered into 3 sections and assigned a value; values for the 3 genes were summed. Although methylation of the OPCML gene was significantly associated with stage, histological types, grade, and ascites and that of RASSF1A and HOXA9 was not, the sum for the 3 genes was significantly associated with stage and ascites. The sum showed higher sensitivity (85.7%) and specificity (100%) for discriminating EOC from normal ovarian tissues than did the methylation status of RASSF1A, OPCML, and HOXA9 (48.6, 77.1, 77.1, and 100, 88.1, 100%, respectively). Combining cancer antigen 125 levels with the sum increased the sensitivity to 94.3%. The detection and analysis of a panel of genes' methylation status with the CCP-based FRET technique may be useful for diagnosis and screening of EOC; the associated cancer antigen 125 can be used to increase diagnostic sensitivity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25966226     DOI: 10.4238/2015.May.4.11

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  7 in total

1.  miRNA-199a-5p suppresses proliferation and invasion by directly targeting NF-κB1 in human ovarian cancer cells.

Authors:  Xiaoxiao Liu; Baofeng Yao; Zhiming Wu
Journal:  Oncol Lett       Date:  2018-07-18       Impact factor: 2.967

Review 2.  Methylation and ovarian cancer: Can DNA methylation be of diagnostic use?

Authors:  Julie L Hentze; Claus K Høgdall; Estrid V Høgdall
Journal:  Mol Clin Oncol       Date:  2019-01-11

3.  Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.

Authors:  Kathleen Conway; Sharon N Edmiston; Joel S Parker; Pei Fen Kuan; Yi-Hsuan Tsai; Pamela A Groben; Daniel C Zedek; Glynis A Scott; Eloise A Parrish; Honglin Hao; Michelle V Pearlstein; Jill S Frank; Craig C Carson; Matthew D Wilkerson; Xiaobei Zhao; Nathaniel A Slater; Stergios J Moschos; David W Ollila; Nancy E Thomas
Journal:  J Invest Dermatol       Date:  2018-12-06       Impact factor: 8.551

4.  Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.

Authors:  Wiphawan Wasenang; Ponlatham Chaiyarit; Siriporn Proungvitaya; Temduang Limpaiboon
Journal:  Clin Epigenetics       Date:  2019-03-04       Impact factor: 6.551

5.  Oncogenic and tumor suppressor function of MEIS and associated factors.

Authors:  Birkan Gİrgİn; Medine KaradaĞ-Alpaslan; Fatih KocabaŞ
Journal:  Turk J Biol       Date:  2020-12-14

6.  A detection panel of novel methylated DNA markers for malignant pleural effusion.

Authors:  Chaonan Liang; Nan Liu; Qin Zhang; Mingming Deng; Jiangwei Ma; Jingwen Lu; Yan Yin; Jian Wang; Yuan Miao; Bin She; Qingchang Li; Gang Hou
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

7.  Casein Kinase 1 Delta Regulates Cell Proliferation, Response to Chemotherapy and Migration in Human Ovarian Cancer Cells.

Authors:  Elena Laura Mazzoldi; Anna Pastò; Elisa Ceppelli; Giorgia Pilotto; Vito Barbieri; Alberto Amadori; Simona Pavan
Journal:  Front Oncol       Date:  2019-11-12       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.